Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 GeneticVariation disease BEFREE Our results denied the role of CYP2C19 polymorphisms for remission after venlafaxine treatment in MDD patients. 31842058 2020
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 GeneticVariation disease BEFREE This study aimed to assess the impact of CYP2D6 and CYP2C19 variation on venlafaxine (VEN) at steady state in patients from Trinidad and Tobago of Indian and African descent with major depressive disorder. 29327975 2018
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 Biomarker disease BEFREE In humans, we found that the absence of CYP2C19 was associated with a bilateral hippocampal volume increase in two independent healthy cohorts (N=386 and 1032) and a lower prevalence of major depressive disorder and depression severity in African-Americans (N=3848). 27895323 2017
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 GeneticVariation disease BEFREE The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. 26343256 2015
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 GeneticVariation disease BEFREE The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder. 24014145 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 Biomarker disease PSYGENET The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. 23081704 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 Biomarker disease PSYGENET The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder. 24014145 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 GeneticVariation disease BEFREE CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. 21861666 2011
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 Biomarker disease PSYGENET CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. 21861666 2011
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 Biomarker disease PSYGENET In 181 subjects with major depressive disorder, drug doses were recorded, imipramine and desipramine plasma concentrations were monitored and CYP2C19 (*2) and CYP2D6 genotype (*3, *4, *5, *6, *9, *10, *41 and gene duplication) were obtained, yielding graded allele-specific CYP2D6 patient groups. 17667959 2008
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.360 Biomarker disease PSYGENET The steady-state plasma concentrations of imipramine and desipramine were measured after a more than 2-week treatment with 0.39 to 1.39 mg/kg/day of imipramine hydrochloride in 28 Japanese patients with major depression who had been phenotyped simultaneously with mephenytoin (for CYP2C19-related status) and with metoprolol (for CYP2D6-related status) before initiating the antidepressant therapy. 8835703 1996